267 related articles for article (PubMed ID: 31117485)
1. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
2. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using
Carrasquillo JA; Fine BM; Pandit-Taskar N; Larson SM; Fleming SE; Fox JJ; Cheal SM; O'Donoghue JA; Ruan S; Ragupathi G; Lyashchenko SK; Humm JL; Scher HI; Gönen M; Williams SP; Danila DC; Morris MJ
J Nucl Med; 2019 Nov; 60(11):1517-1523. PubMed ID: 31053681
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Doran MG; Watson PA; Cheal SM; Spratt DE; Wongvipat J; Steckler JM; Carrasquillo JA; Evans MJ; Lewis JS
J Nucl Med; 2014 Dec; 55(12):2045-9. PubMed ID: 25453051
[TBL] [Abstract][Full Text] [Related]
5. Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.
Hintz HM; Gallant JP; Vander Griend DJ; Coleman IM; Nelson PS; LeBeau AM
Clin Cancer Res; 2020 Sep; 26(18):4882-4891. PubMed ID: 32636317
[TBL] [Abstract][Full Text] [Related]
6. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
[TBL] [Abstract][Full Text] [Related]
7. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Pandit-Taskar N; O'Donoghue JA; Beylergil V; Lyashchenko S; Ruan S; Solomon SB; Durack JC; Carrasquillo JA; Lefkowitz RA; Gonen M; Lewis JS; Holland JP; Cheal SM; Reuter VE; Osborne JR; Loda MF; Smith-Jones PM; Weber WA; Bander NH; Scher HI; Morris MJ; Larson SM
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2093-105. PubMed ID: 25143071
[TBL] [Abstract][Full Text] [Related]
8. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human Evaluation of Site-Specifically Labeled
Yeh R; O'Donoghue JA; Jayaprakasam VS; Mauguen A; Min R; Park S; Brockway JP; Bromberg JF; Zhi WI; Robson ME; Sanford R; Modi S; Agnew BJ; Lyashchenko SK; Lewis JS; Ulaner GA; Zeglis BM
J Nucl Med; 2024 Mar; 65(3):386-393. PubMed ID: 38272704
[TBL] [Abstract][Full Text] [Related]
10. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
11. First-in-Humans Imaging with
Pandit-Taskar N; Postow MA; Hellmann MD; Harding JJ; Barker CA; O'Donoghue JA; Ziolkowska M; Ruan S; Lyashchenko SK; Tsai F; Farwell M; Mitchell TC; Korn R; Le W; Lewis JS; Weber WA; Behera D; Wilson I; Gordon M; Wu AM; Wolchok JD
J Nucl Med; 2020 Apr; 61(4):512-519. PubMed ID: 31586002
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
Pandit-Taskar N; O'Donoghue JA; Ruan S; Lyashchenko SK; Carrasquillo JA; Heller G; Martinez DF; Cheal SM; Lewis JS; Fleisher M; Keppler JS; Reiter RE; Wu AM; Weber WA; Scher HI; Larson SM; Morris MJ
J Nucl Med; 2016 Dec; 57(12):1858-1864. PubMed ID: 27516450
[TBL] [Abstract][Full Text] [Related]
13. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
[TBL] [Abstract][Full Text] [Related]
14. Comparative biodistribution analysis across four different
Bensch F; Smeenk MM; van Es SC; de Jong JR; Schröder CP; Oosting SF; Lub-de Hooge MN; Menke-van der Houven van Oordt CW; Brouwers AH; Boellaard R; de Vries EGE
Theranostics; 2018; 8(16):4295-4304. PubMed ID: 30214621
[No Abstract] [Full Text] [Related]
15. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
16. A radiopharmaceutical [
Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
[TBL] [Abstract][Full Text] [Related]
18. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
19. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO
Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
Danila DC; Szmulewitz RZ; Vaishampayan U; Higano CS; Baron AD; Gilbert HN; Brunstein F; Milojic-Blair M; Wang B; Kabbarah O; Mamounas M; Fine BM; Maslyar DJ; Ungewickell A; Scher HI
J Clin Oncol; 2019 Dec; 37(36):3518-3527. PubMed ID: 31689155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
